Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes. METHODS: We conducted a retrospective analysis of 235 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, P Connor, Jacobson, Caron, Yi, Alisha, Gaballa, Mahmoud R, Horick, Nora, Rabideau, Dustin J, Lindell, Kevin, DePinho, Gabriel D, El-Jawahri, Areej R, Frigault, Matthew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472144/
http://dx.doi.org/10.1136/jitc-2022-004567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472144/
http://dx.doi.org/10.1136/jitc-2022-004567

Ejemplares similares